摘要
糖尿病性黄斑水肿（DME）是糖尿病患者视力损害的主要原因，随着对DME研究的不断深入和对DME认识的加深，其治疗方法不断进步。继标准的激光光凝和玻璃体切除手术之后，眼内注射糖皮质激素和抗血管生成药物等方法有望从其发病机制方面治疗DME，并大大改善视力，其安全性和有效性已通过一系列随机双盲临床试验得到证实。在对DME的定义、分类、发病机制正确认识的基础上，对DME的治疗方法进行介绍，并对抗血管生成药物，特别是ranibizumab的研究情况进行总结，以帮助临床医师更好地把握DME的治疗指征，选择合理的治疗方法。
Diabetic macular edema （DME） is one of causes leading to visual acuity loss in the diabetic population. In recent years,great progress has been achieved in the treatment for DME. While laser photocoagulation and pars plana vitrectomy remain the standard of care, a new wave of methods,including intravitreal corticosteroid and antivascular endothelial growth factor （antiVEGF） medications, is emerging and shows the preliminary safety and efficacy profile for DME by a number of clinical trials. This article introduce the definition,classification,pathogenesis and the different treatment methods for DME,so to aid ophthalmologists in evaluating the most appropriate and upto date management options in managing DME. Particular attention is paid to summarize recent peerreviewed literatures of ranibizumab （Lucentis）.
出处
《中华实验眼科杂志》
CAS
CSCD
北大核心
2012年第2期97-100,共4页
Chinese Journal Of Experimental Ophthalmology
